IPP Bureau
Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
By IPP Bureau - June 17, 2024
Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,
Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
By IPP Bureau - June 17, 2024
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Imfinzi approved in the US for endometrial cancer
By IPP Bureau - June 17, 2024
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Alembic announces USFDA final approval for Icatibant injection
By IPP Bureau - June 17, 2024
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27%
By IPP Bureau - June 17, 2024
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
USFDA approves next-gen TKI Augtyro for treatment of solid tumors
By IPP Bureau - June 17, 2024
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Health Minister Nadda aims to attain targeted Health goals in the first 100 days of formation of new government
By IPP Bureau - June 15, 2024
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
Fischer Medical Ventures and The Therapy Platform partner for mental healthcare
By IPP Bureau - June 15, 2024
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Jubilant Draximage to invest US$ 50 million to expand its PET radiopharmacy network
By IPP Bureau - June 15, 2024
Jubilant's Radiopharma Business to expand positron emission tomography radiopharmacy network
Sun Pharma and Moebius Medical present Phase 2b study on MM-II
By IPP Bureau - June 15, 2024
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Jubilant Pharmova announces voluntary prepayment of US$ 75 million term loan
By IPP Bureau - June 15, 2024
As on 31st March 2024, Jubilant Pharmova Limited reported Gross Debt at Rs. 3,414 crore
Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine
By IPP Bureau - June 14, 2024
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
By IPP Bureau - June 14, 2024
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
Farxiga approved in the US for the treatment of paediatric type-2 diabetes
By IPP Bureau - June 14, 2024
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
